Linked Life Data

14700452

Source:http://linkedlifedata.com/resource/pubmed/id/14700452

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2003-12-31
pubmed:abstractText
Frequently, patients suffering from depressive disorders discontinue antidepressant treatment due to the unpleasant side effects of these medications, particularly in the first month of therapy. Good tolerability (particularly in the early stages of treatment), patient education, and the quality of the relationship between physicians and patients are all common determining factors of patient adherence. Controlled-release antidepressant agents have the potential to improve tolerability early in the course of therapy, one of the most likely periods of dropout from treatment. Side effects for controlled-release formulations are often more favorable because controlled-release formulations exhibit lower peak plasma drug concentrations when compared with immediate-release formulations. Venlafaxine extended-release (XR), bupropion sustained-release (SR), and paroxetine controlled-release (CR) are 3 commonly utilized controlled-release antidepressants that have demonstrated improvement over their immediate-release predecessors in reducing certain adverse effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0160-6689
pubmed:author
pubmed:issnType
Print
pubmed:volume
64 Suppl 18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
25-30
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Improving antidepressant adherence.
pubmed:affiliation
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA. cnemero@emory.edu
pubmed:publicationType
Journal Article, Review